The estimated Net Worth of Thomas Patrick Kelly is at least $4.45 Миллион dollars as of 15 February 2024. Mr. Kelly owns over 3,010 units of Deciphera Pharmaceuticals Inc stock worth over $2,056,157 and over the last 17 years he sold DCPH stock worth over $305,555. In addition, he makes $2,086,680 as Chief Financial Officer, Executive Vice President и Treasurer at Deciphera Pharmaceuticals Inc.
Thomas has made over 25 trades of the Deciphera Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 3,010 units of DCPH stock worth $47,016 on 15 February 2024.
The largest trade he's ever made was exercising 40,000 units of Deciphera Pharmaceuticals Inc stock on 23 December 2019 worth over $75,600. On average, Thomas trades about 4,401 units every 177 days since 2007. As of 15 February 2024 he still owns at least 80,350 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kelly stock trades at the bottom of the page.
Thomas J. Kelly serves as Chief Financial Officer, Executive Vice President, Treasurer of the Company. Mr. Kelly has served as our Executive Vice President, Chief Financial Officer and Treasurer since January 2019 and as our Chief Financial Officer and Treasurer since February 2015. Prior to joining Deciphera, Mr. Kelly served as Chief Financial Officer of AdvanDx, Inc., a private molecular diagnostics company, from 2012 to 2014. Prior to joining AdvanDx, Mr. Kelly served as chief financial officer for various public and private life science companies, including deCODE genetics, Inc. from 2010 to 2011 and Critical Therapeutics, Inc. from 2007 to 2008. Prior to joining Critical Therapeutics, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams and was an attorney in the corporate and securities group of Foley, Hoag and Elliot, LLP. Mr. Kelly holds a J.D. with honors degree from the University of Chicago Law School and a B.S. in Foreign Services degree cum laude from the Georgetown University School of Foreign Service.
As the Chief Financial Officer, Executive Vice President и Treasurer of Deciphera Pharmaceuticals Inc, the total compensation of Thomas Kelly at Deciphera Pharmaceuticals Inc is $2,086,680. There are 3 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
Thomas Kelly is 49, he's been the Chief Financial Officer, Executive Vice President и Treasurer of Deciphera Pharmaceuticals Inc since 2019. There are 17 older and 2 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar и Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: